<DOC>
	<DOCNO>NCT00489294</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics Syntropin ( human growth hormone ) determine serum concentration IGF-1 Syntropin injection .</brief_summary>
	<brief_title>Safety Study Syntropin ( Human Growth Hormone ) Treatment Growth Hormone Deficiency</brief_title>
	<detailed_description>Syntropin administer subcutaneous injection . Eligible patient receive subcutaneous injection octreodite ( suppress endogenous growth hormone secretion ) 12 hour , immediately prior , 12 hour schedule injection growth hormone .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female subject age 18 45 year ( inclusive ) . Written inform consent participate study . Body mass index 19 31 kg/mÂ² . Female subject childbearing potential , define surgically sterile least 2 year postmenopausal , must agree use one follow form contraception 3 month prior 7 day follow last dose study drug : hormonal ( oral , transdermal , implant , injection ) , barrier ( condom , diaphragm spermicide ) , IUD , vasectomize partner ( 6 month minimum ) . Subjects must use method least 3 month prior start study . No clinically significant abnormal finding physical examination , medical history , electrocardiogram , clinical laboratory result screen . Screening growth hormone insulinlike growth factor I ( IGFI ) within normal limit . Exclusion Criteria A history clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition , opinion Principle Investigator , would jeopardize safety subject impact validity study result . A history allergic adverse response growth hormone , glycerin , metacresol , comparable similar product . Subjects ( whatever reason ) abnormal diet four week precede study . Subjects donate blood within 30 day plasma within 14 day first study dose . Participation clinical trial within 30 day prior study initiation . Use overthecounter ( OTC ) medication , include vitamin , within 7 day prior study . Use prescription medication within 14 day prior study , exception hormonal contraceptive woman childbearing potential . Treatment known enzyme alter drug barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior study . Smoking use tobacco product within 6 month prior study . Female subject try conceive , pregnant , lactate . Positive serum pregnancy test screen urine pregnancy test prior drug administration woman regardless childbearing potential . Positive blood screen HIV , Hepatitis B surface antigen ( HbSAg ) , Hepatitis C , positive urine screen alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Human growth hormone</keyword>
	<keyword>idiopathic short stature</keyword>
	<keyword>short stature</keyword>
</DOC>